Gesynta Pharma (Sweden)
Gesynta Pharma develops pharmaceutical treatments of inflammation – a key underlying driver in a spectrum of diseases. The most advanced drug candidate, vipoglanstat, is currently in development as a non-hormonal, non-opioid, disease-modifying treatment of endometriosis – a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Vipoglanstat selectively inhibits mPGES-1, an enzyme that promotes production of the proinflammatory mediator prostaglandin E2 (
Basic Information
- Category: business
- Website: https://www.gesynta.se/
Documented Facts
- Email: info@gesynta.se (No linked source recorded for this statement.)
Evidence and Sources
- Gesynta Pharma (Sweden) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Gesynta Pharma (Sweden).
- Canonical profile: https://brandsource.ai/brands/gesynta-pharma-sweden
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/gesynta-pharma-sweden/json-ld
- Citation profile API: https://brandsource.ai/api/brands/gesynta-pharma-sweden/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Gesynta Pharma develops pharmaceutical treatments of inflammation – a key underlying driver in a spectrum of diseases. The most advanced drug candidate, vipoglanstat, is currently in development as a non-hormonal, non-opioid, disease-modifying treatment of endometriosis – a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Vipoglanstat selectively inhibits mPGES-1, an enzyme that promotes production of the proinflammatory mediator prostaglandin E2 (
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.